Alyssa Aikman
Psychiatric/Mental Health · Vancouver, WANPI 1194348508
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 198 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,425, 7.6 times the $188 reported in 2022. Among psychiatric/mental health clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 198 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$568
- Vanda Pharmaceuticals Inc.$338
- Corium, LLC$246
- Ironshore Pharmaceuticals Inc.$242
- Otsuka America Pharmaceutical, Inc.$236
- Lundbeck LLC$214
- plus $1K from 12 others
What the payments were for
- Food & beverage$3,319100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 49 | $568 |
| Vanda Pharmaceuticals Inc. | 15 | $338 |
| Corium, LLC | 14 | $246 |
| Ironshore Pharmaceuticals Inc. | 20 | $242 |
| Otsuka America Pharmaceutical, Inc. | 8 | $236 |
| Lundbeck LLC | 11 | $214 |
| Alkermes, Inc. | 10 | $187 |
| Supernus Pharmaceuticals, Inc. | 17 | $173 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $170 |
| Johnson & Johnson | 8 | $163 |
| Neurocrine Biosciences, Inc. | 7 | $149 |
| Bausch Health US, LLC | 7 | $144 |
| Teva Pharmaceuticals USA, Inc. | 6 | $126 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $124 |
| Axsome Therapeutics, Inc. | 3 | $67 |
| Noven Therapeutics, LLC | 3 | $64 |
| E.r. Squibb & Sons, L.L.C. | 2 | $63 |
| Collegium Pharmaceutical, Inc. | 2 | $44 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$125
How this compares
$3,319 in reported general payments places this provider in the 90th percentile of 931 psychiatric/mental health providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 14 | $1,823 |
| Clonazepam | 11 | $101 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Vancouver
- Brendan RoeVancouver$18K
- Rhonda RowanVancouver$10K
- John JohnsonVancouver$8K
- Nwamaka EmeruemVancouver$8K
- Hsiangfeng TsaiVancouver$5K
- David CaliffVancouver$4K
- Cailin JarrellVancouver$4K
- Angela CombsRichland$121K
- Ashley McGinnisAuburn$26K
- Courtney YantPuyallup$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.